Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete rem...
Outlook for 2025 earnings raisedRoche expects an increase in Group sales in the mid single digit range (CER). Core earnings per...
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated population...
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III R...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 ...
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer...
